Stanley Hsia to Hypoglycemic Agents
This is a "connection" page, showing publications Stanley Hsia has written about Hypoglycemic Agents.
Connection Strength
1.586
-
Machinani S, Bazargan-Hejazi S, Hsia SH. Psychological insulin resistance among low-income, U.S. racial minority patients with type 2 diabetes. Prim Care Diabetes. 2013 Apr; 7(1):51-5.
Score: 0.384
-
Hsia SH, Navar MD, Duran P, Shaheen M, Davidson MB. Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. Endocr Pract. 2011 Sep-Oct; 17(5):691-8.
Score: 0.351
-
Hsia SH, Davidson MB. Established therapies for diabetes mellitus. Curr Med Res Opin. 2002; 18 Suppl 1:s13-21.
Score: 0.179
-
Frias JP, Bonora E, Nev?rez Ruiz L, Hsia SH, Jung H, Raha S, Cox DA, Bethel MA, Konig M. Efficacy and safety of dulaglutide 3.0?and 4.5?mg in patients aged?younger than?65 and?65?years or older: Post hoc analysis of the AWARD-11 trial. Diabetes Obes Metab. 2021 10; 23(10):2279-2288.
Score: 0.173
-
Desouza CV, Holcomb RG, Rosenstock J, Frias JP, Hsia SH, Klein EJ, Zhou R, Kohzuma T, Fonseca VA. Results of a Study Comparing Glycated Albumin to Other Glycemic Indices. J Clin Endocrinol Metab. 2020 03 01; 105(3).
Score: 0.158
-
Hsia SH, Duran P, Lee ML, Davidson MB. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes. 2020 Jan; 12(1):91-94.
Score: 0.154
-
Hsia SH. Insulin glargine compared to NPH among insulin-na?ve, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Res Clin Pract. 2011 Mar; 91(3):293-9.
Score: 0.083
-
Hsia SH, Bazargan M, Davidson MB. Effect of Pancreas Tonic (an ayurvedic herbal supplement) in type 2 diabetes mellitus. Metabolism. 2004 Sep; 53(9):1166-73.
Score: 0.054
-
Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Robins D. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023 08 05; 402(10400):472-483.
Score: 0.050